PMID- 32001076
OWN - NLM
STAT- MEDLINE
DCOM- 20201006
LR  - 20231018
IS  - 1095-6859 (Electronic)
IS  - 0090-8258 (Linking)
VI  - 157
IP  - 1
DP  - 2020 Apr
TI  - Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice 
      patterns and patient outcomes.
PG  - 36-45
LID - S0090-8258(20)30063-9 [pii]
LID - 10.1016/j.ygyno.2020.01.021 [doi]
AB  - OBJECTIVE: Patients with advanced low-grade serous carcinoma (LGSC) have poor 
      long-term survival rates. As a rare histotype, there are uncertainties regarding 
      the use of current therapies. Thus, we studied practice patterns and treatment 
      outcomes as part of a national initiative to better understand and improve the 
      care of women with advanced LGSC. METHODS: This retrospective cohort study was 
      conducted in 5 Canadian referral institutions from 2000 to 2016. Data collection 
      and pathology reporting were standardized. Outcome measures included overall 
      survival (OS), progression-free survival (PFS), progression-free intervals (PFI), 
      and time to next treatment (TTNT). Cox regression analysis was used to evaluate 
      the effects of clinical and pathologic factors on outcomes and prognosis. 
      RESULTS: There were 134 patients (stage II-IV) with a median follow-up of 
      32.4 months (range 1.6-228). Four primary treatments were compared across 
      institutions: 1) surgery followed by chemotherapy (56%), 2) neoadjuvant 
      chemotherapy (NACT) followed by surgery (27%), 3) surgery alone (9%), and 4) 
      surgery followed by anti-hormone therapy (4%). Primary platinum/paclitaxel 
      chemotherapy was used in 81%. Patients treated with NACT had worse PFS. 
      Multivariable Cox regression analysis identified lesser residual disease, younger 
      age, and primary peritoneal origin as variables significantly associated with 
      better OS/PFS (p < 0.03). One institution had significantly better PFS than the 
      others (p = 0.025), but this finding could be related to a higher frequency of 
      primary peritoneal LGSC. PFI and TTNT intervals in patients with relapsed disease 
      were not significantly different after the first relapse irrespective of 
      treatment type. CONCLUSIONS: There are notable differences in practice patterns 
      across Canada. This underscores the need for ongoing strategies to measure, 
      evaluate and achieve optimal patient outcomes for women with advanced LGSC.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Scott, Stephanie A
AU  - Scott SA
AD  - Department of Obstetrics and Gynecology, Dalhousie University, Halifax, Nova 
      Scotia, Canada. Electronic address: StephanieA.scott@nshealth.ca.
FAU - Llaurado Fernandez, Marta
AU  - Llaurado Fernandez M
AD  - Department of Obstetrics and Gynecology, University of British Columbia, 
      Vancouver, British Columbia, Canada.
FAU - Kim, Hannah
AU  - Kim H
AD  - Department of Obstetrics and Gynecology, University of British Columbia, 
      Vancouver, British Columbia, Canada.
FAU - Elit, Laurie
AU  - Elit L
AD  - Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, Ontario, Canada.
FAU - Nourmoussavi, Melica
AU  - Nourmoussavi M
AD  - Division of Gynecologic-Oncology, Centre Hospitalier de Universite de Montreal, 
      (CHUM) and Centre de recherche du CHUM, Montreal, Quebec, Canada.
FAU - Glaze, Sarah
AU  - Glaze S
AD  - Tom Baker Cancer Centre, Alberta Health Services, Calgary, Alberta, Canada.
FAU - Roberts, Lesley
AU  - Roberts L
AD  - Department of Obstetrics and Gynecology, Dalhousie University, Halifax, Nova 
      Scotia, Canada.
FAU - Offman, Saul L
AU  - Offman SL
AD  - Department of Obstetrics and Gynecology, Dalhousie University, Halifax, Nova 
      Scotia, Canada.
FAU - Rahimi, Kurosh
AU  - Rahimi K
AD  - Department of Pathology, Centre Hospitalier de l'Universite de Montreal, 
      Montreal, Quebec, Canada.
FAU - Lytwyn, Alice
AU  - Lytwyn A
AD  - Department of Pathology and Molecular Medicine, Health Research Methods, 
      Evaluation, and Impact (HEI), McMaster University, Hamilton, Ontario, Canada.
FAU - Sur, Monalisa
AU  - Sur M
AD  - Department of Pathology and Molecular Medicine, McMaster University and The 
      Juravinski Hospital and Cancer Centre, Hamilton, Ontario, Canada.
FAU - Gilks, C Blake
AU  - Gilks CB
AD  - Department of Obstetrics and Gynecology, University of British Columbia, 
      Vancouver, British Columbia, Canada.
FAU - Matheson, Kara
AU  - Matheson K
AD  - Department of Obstetrics and Gynecology, Dalhousie University, Halifax, Nova 
      Scotia, Canada.
FAU - Kobel, Martin
AU  - Kobel M
AD  - Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, 
      Alberta, Canada.
FAU - Dawson, Amy
AU  - Dawson A
AD  - Department of Obstetrics and Gynecology, University of British Columbia, 
      Vancouver, British Columbia, Canada.
FAU - Tinker, Anna V
AU  - Tinker AV
AD  - Department of Obstetrics and Gynecology, University of British Columbia, 
      Vancouver, British Columbia, Canada.
FAU - Kwon, Janice S
AU  - Kwon JS
AD  - Department of Obstetrics and Gynecology, University of British Columbia, 
      Vancouver, British Columbia, Canada.
FAU - Hoskins, Paul
AU  - Hoskins P
AD  - Department of Obstetrics and Gynecology, University of British Columbia, 
      Vancouver, British Columbia, Canada.
FAU - Santos, Jennifer L
AU  - Santos JL
AD  - Department of Obstetrics and Gynecology, University of British Columbia, 
      Vancouver, British Columbia, Canada.
FAU - Cheung, Andrea
AU  - Cheung A
AD  - Department of Obstetrics and Gynecology, University of British Columbia, 
      Vancouver, British Columbia, Canada.
FAU - Provencher, Diane
AU  - Provencher D
AD  - Division of Gynecologic-Oncology, Centre Hospitalier de Universite de Montreal, 
      (CHUM) and Centre de recherche du CHUM, Montreal, Quebec, Canada.
FAU - Carey, Mark S
AU  - Carey MS
AD  - Department of Obstetrics and Gynecology, University of British Columbia, 
      Vancouver, British Columbia, Canada.
CN  - Canadian LGSC Community of Practice (GOC-CoP)
LA  - eng
GR  - NRF 152680/CIHR/Canada
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20200127
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
RN  - BG3F62OND5 (Carboplatin)
RN  - P88XT4IS4D (Paclitaxel)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
EIN - Gynecol Oncol. 2022 Nov;167(2):399. PMID: 37850594
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Carboplatin/administration & dosage
MH  - Cisplatin/administration & dosage
MH  - Cohort Studies
MH  - Cystadenocarcinoma, Serous/*drug therapy/pathology/*surgery
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Ovarian Neoplasms/*drug therapy/pathology/*surgery
MH  - Paclitaxel/administration & dosage
MH  - *Practice Patterns, Physicians'
MH  - Progression-Free Survival
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Low-grade serous carcinoma
OT  - Outcomes
OT  - Ovarian cancer
OT  - Practice patterns
COIS- Declaration of competing interest Dr. Carey has previously held shares in Array 
      Biopharma, Kazia pharmaceuticals and Merck.
EDAT- 2020/02/01 06:00
MHDA- 2020/10/07 06:00
CRDT- 2020/02/01 06:00
PHST- 2019/08/23 00:00 [received]
PHST- 2019/11/28 00:00 [revised]
PHST- 2020/01/13 00:00 [accepted]
PHST- 2020/02/01 06:00 [pubmed]
PHST- 2020/10/07 06:00 [medline]
PHST- 2020/02/01 06:00 [entrez]
AID - S0090-8258(20)30063-9 [pii]
AID - 10.1016/j.ygyno.2020.01.021 [doi]
PST - ppublish
SO  - Gynecol Oncol. 2020 Apr;157(1):36-45. doi: 10.1016/j.ygyno.2020.01.021. Epub 2020 
      Jan 27.